Literature DB >> 23318790

Role of matrix β-1,3 glucan in antifungal resistance of non-albicans Candida biofilms.

K F Mitchell1, H T Taff, M A Cuevas, E L Reinicke, H Sanchez, D R Andes.   

Abstract

Candida biofilm infections pose an increasing threat in the health care setting due to the drug resistance associated with this lifestyle. Several mechanisms underlie the resistance phenomenon. In Candida albicans, one mechanism involves drug impedance by the biofilm matrix linked to β-1,3 glucan. Here, we show this is important for other Candida spp. We identified β-1,3 glucan in the matrix, found that the matrix sequesters antifungal drug, and enhanced antifungal susceptibility with matrix β-1,3 glucan hydrolysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318790      PMCID: PMC3623361          DOI: 10.1128/AAC.02378-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex.

Authors:  Analy S Melo; Fernando C Bizerra; Edna Freymüller; Beth A Arthington-Skaggs; Arnaldo L Colombo
Journal:  Med Mycol       Date:  2010-11-02       Impact factor: 4.076

2.  Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms.

Authors:  Gordon Ramage; Stefano Bachmann; Thomas F Patterson; Brian L Wickes; José L López-Ribot
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

3.  Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay.

Authors:  Jeniel E Nett; Michael T Cain; Kyler Crawford; David R Andes
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

4.  Candida albicans biofilms produce antifungal-tolerant persister cells.

Authors:  Michael D LaFleur; Carol A Kumamoto; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-08-21       Impact factor: 5.191

5.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

6.  Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.

Authors:  Jeniel Nett; Leslie Lincoln; Karen Marchillo; Randall Massey; Kathleen Holoyda; Brian Hoff; Michelle VanHandel; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-11-27       Impact factor: 5.191

7.  Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  J Med Microbiol       Date:  2006-08       Impact factor: 2.472

Review 8.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Improvement of XTT assay performance for studies involving Candida albicans biofilms.

Authors:  Wander José da Silva; Jayampath Seneviratne; Nipuna Parahitiyawa; Edvaldo Antonio Ribeiro Rosa; Lakshman Perera Samaranayake; Altair Antoninha Del Bel Cury
Journal:  Braz Dent J       Date:  2008

10.  Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols.

Authors:  Pranab K Mukherjee; Jyotsna Chandra; Duncan M Kuhn; Mahmoud A Ghannoum
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more
  42 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 2.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

3.  Antifungal Properties of Cationic Phenylene Ethynylenes and Their Impact on β-Glucan Exposure.

Authors:  Harry C Pappas; Rina Sylejmani; Matthew S Graus; Patrick L Donabedian; David G Whitten; Aaron K Neumann
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 4.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 5.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 6.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

Review 7.  Fungal biofilms, drug resistance, and recurrent infection.

Authors:  Jigar V Desai; Aaron P Mitchell; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

Review 8.  Mechanisms of Candida biofilm drug resistance.

Authors:  Heather T Taff; Kaitlin F Mitchell; Jessica A Edward; David R Andes
Journal:  Future Microbiol       Date:  2013-10       Impact factor: 3.165

9.  Characterization of biofilm formation and the role of BCR1 in clinical isolates of Candida parapsilosis.

Authors:  Srisuda Pannanusorn; Bernardo Ramírez-Zavala; Heinrich Lünsdorf; Birgitta Agerberth; Joachim Morschhäuser; Ute Römling
Journal:  Eukaryot Cell       Date:  2013-12-02

Review 10.  Biofilm Exopolysaccharides of Pathogenic Fungi: Lessons from Bacteria.

Authors:  Donald C Sheppard; P Lynne Howell
Journal:  J Biol Chem       Date:  2016-04-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.